drug · antibody
retifanlimab
Marketedupdated 3mo agoby $INCY INCYTE CORP🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 16 investigational indications.
targets
Programmed cell death protein 1
all catalysts(6)
approval · 5
Mar 22, 2023
approval
$INCY122.22+1.71%
ZYNYZ (RETIFANLIMAB-DLWR) — FDA approval
retifanlimab
→
Apr 22, 2024
approval
$INCY122.22+1.71%
ZYNYZ (RETIFANLIMAB-DLWR) — FDA approval
retifanlimab
→
May 15, 2025
approval
$INCY122.22+1.71%
ZYNYZ (RETIFANLIMAB-DLWR) — FDA approval
retifanlimab
→
Dec 17, 2025
approval
$INCY122.22+1.71%
ZYNYZ (RETIFANLIMAB-DLWR) — FDA approval
retifanlimab
→
Mar 30, 2026
approval
$INCY122.22+1.71%
ZYNYZ (RETIFANLIMAB-DLWR) — FDA approval
retifanlimab
→
Trials studying retifanlimab
- phase3Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- phase1A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- phase1Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
- EP1A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma
- phase2Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- phase3Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- phase2Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- phase2Combination Study of SV-BR-1-GM With Retifanlimab
News(4)
- Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drugScholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…fiercebiotech · 7d ago
- Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen optionsIncyte has ditched a JAK2 inhibitor in phase 1 development for a rare blood cancer in favor of “next-generation” replacements.fiercebiotech · 20d ago
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 3mo ago
- Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal CancerAparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.onclive · 3mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that